Nova Eye Medical concluded a $5.1 million placement and institutional entitlement offer, part of an $8 million capital raise.
The funds will accelerate growth in the glaucoma business, expanding the iTrackTM Advance sales in the US and European markets and diversifying the glaucoma surgical device portfolio.
A fully underwritten retail entitlement offer targeting $2.9 million is forthcoming.
The offer price was 21 cents per new share, with settlement on Feb. 22.